You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR receptor positive HER2 receptor negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

    Not yet recruiting
    • Breast Cancer Invasive
    • +3 more
    • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Nov 17, 2023

    HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

    Recruiting
    • HER2-positive Breast Cancer
    • +17 more
    • ALX148
    • Fam-Trastuzumab Deruxtecan-Nxki
    • Chicago, Illinois
    • +1 more
    May 19, 2023

    Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Aug 4, 2023

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Ocala, Florida
      Ocala Oncology Center PL DBA Florida Cancer Affiliates
    Jul 19, 2023

    Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Boston

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Nov 3, 2022

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Washington, District of Columbia
    • +4 more
    Jan 31, 2023

    Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

    Recruiting
    • Breast Neoplasm
    • +4 more
    • PIK3CA inhibitor
    • +12 more
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jan 2, 2023

    Advanced or Metastatic Breast Cancer Trial (PF-07220060, Fulvestrant, Everolimus)

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • (no location specified)
    Oct 24, 2023

    Breast Cancer Trial (Inavolisib, Fulvestrant, Alpelisib)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Jan 30, 2023

    Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Stanford, California
      Stanford University
    Nov 16, 2022

    Invasive Breast Cancer Trial in Milwaukee (Cemiplimab, Paclitaxel, Carboplatin (not mandatory))

    Recruiting
    • Invasive Breast Cancer
    • Milwaukee, Wisconsin
      Froedtert Hospital & Medical College of Wisconsin
    Apr 1, 2022

    Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

    Recruiting
    • Brain Metastases
    • HR+ Metastatic Breast Cancer
    • Stereotactic Radiosurgery (SRS)
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 1, 2022

    Breast Cancer Trial in Guangzhou (Capecitabine, Aromatase Inhibitor)

    Active, not recruiting
    • Breast Cancer
    • Guangzhou, Guangdong, China
      State Key Laboratory of Oncology in South China, Sun Yat-sen Uni
    Jan 27, 2023

    Breast Cancer, Chemo Effect Trial (Capecitabine)

    Not yet recruiting
    • Breast Cancer
    • Chemotherapy Effect
    • (no location specified)
    Mar 9, 2022

    A NIS of Alpelisib in Combination With Fulvestrant in

    Not yet recruiting
    • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
    • Alpelisib
    • Fulvestrant
    • (no location specified)
    Aug 9, 2022

    Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

    Not yet recruiting
    • Breast Cancer
    • Marseille, France
      Institut Paoli Calmettes
    Aug 9, 2023

    Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

    Recruiting
    • Locally Advanced Breast Cancer
    • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
    • Jinan, Shandong, China
      Breast Cancer Center, Shandong Cancer Hospital and Institute
    Apr 11, 2023

    Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in

    Not yet recruiting
    • Anatomic Stage II Breast Cancer AJCC v8
    • +3 more
    • Biospecimen Collection
    • +7 more
    • Portland, Oregon
      SWOG
    Sep 27, 2023